<h4>Aims</h4>Glucagon-like peptide-1 (GLP-1) and glucagon dual receptor agonists are in clinical development for a range of metabolic conditions, including type 2 diabetes and obesity. This evidence concerns the gene GCG and obesity due to melanocortin 4 receptor deficiency.